Buy ALD-52 for sale online from USA vendor
Discount program: 5% OFF for the second order, 7% OFF for the third order.
Shop with us securely! We offer re-shipment guarantees.
We always provide new, legal products of impeccable quality.
Please make sure that the product is legal in your country and not under any restrictions before ordering.
We do not sell pharmaceutical products or controlled substances.
What is ALD-52?
ALD-52, often known as 1-acetyl-LSD, is a lysergic acid diethylamide analogue (LSD). It was developed in 1957 by the renowned chemist Albert Hofmann, but it did not gain widespread appeal and scientific research until the 1960s, amid the emergence of psychedelics. This essay will examine the history and science of ALD-52 and its influence on the psychedelics community.
History of ALD-52
In the middle of the 20th century, psychedelics were in their infancy, and LSD was almost unknown. However, everything changed when Albert Hofmann discovered ALD-52. When Hofmann discovered ALD-52, he was a Swiss chemist working for the pharmaceutical business Sandoz Laboratories. Despite its discovery, ALD-52 was not explored extensively until the 1960s, when psychedelics became prominent.
Science of ALD-52
ALD-52 is a chemical analogue of LSD, indicating that it has a similar structure to LSD but with minor structural differences. The existence of an acetyl group linked to the nitrogen atom of the molecule is one of these variances. This minor modification significantly alters the molecule's actions, distinguishing it from LSD.
ALD-52 is a moderately potent agonist for serotonin receptors in the brain, affecting perceptual, cognition, and mood changes. It also alters the user's perception of time, resulting in a skewed sense of time. Similar to other psychedelics, ALD-52 can induce strong and, at times, overpowering sensations, which can be both pleasant and sour.
Impact of ALD-52 on the World of Psychedelics
Despite its discovery in the 1950s, ALD-52's effect on the psychedelics community did not become evident until the 1960s. ALD-52 was among the numerous new psychedelics being investigated at this time, and its influence was tremendous. It ushered in a new age of psychedelic study and enhanced our understanding of these substances and their effects.
However, it is essential to remember that ALD-52 and other psychedelics are harmful and banned in many countries. The recreational use of ALD-52 can result in severe health issues and even death; hence it is not recommended.
In conclusion
ALD-52 is a remarkable molecule with a long and influential history in the psychedelics community. Despite its risks, it remains a significant aspect of psychedelic history and is still studied today. Nonetheless, it is essential to approach the usage of ALD-52 with caution and to be aware of the associated hazards. As is the case with other psychedelics, ALD-52 should only be used under the supervision of a medical practitioner in a controlled environment.
To prepare the content, the following materials were used:
- FDA Substance Registration System
- Hazardous Substances Data Bank. National Library of Medicine. 28 August 2008. Retrieved 22 August 2014. 3,4-Methylenedioxymethamphetamine
- Liver transplant modulates gut microbial dysbiosis and cognitive function in cirrhosis. PDF . By HoChong Gilles, Scott C Matherly, Mohammed S Siddiqui, Puneet Puri...
- Differential impact of hyponatremia and hepatic encephalopathy on health-related quality of life and brain metabolite abnormalities in cirrhosis . By Jasmohan Bajaj
- An overview of alcohol and other drug issues
- Medicating the mind: a Kantian analysis of overprescribing psychoactive drugs B A Manninen
- The pharmacological basis of opioids Carla Ghelardini, Lorenzo Di Cesare Mannelli and Enrica Bianchi
- Ask Dr. Shulgin Online ARCHIVE: June 3, 2004
- Inhibition of plasma membrane monoamine transporters by β-ketoamphetamines. Nicholas V Cozzi, Michael KSievert, Alexander T Shulgin, Peyton JacobIII, Arnold Eruoho
- Schedules of Controlled Substances: Placement of Methylone Into Schedule I
- Bioanalysis of new designer drugs. Wohlfarth A, Weinmann W.
- New Psychoactive Substances (including synthetic cannabinoids, mephedrone, and more)
- Future Synthetic Drugs of Abuse. Donald A. Cooper. Drug Enforcement Administration McLean, Virginia
- Designer drugs: a medicinal chemistry perspective. F. Ivy Carroll Anita H. Lewin S. Wayne Mascarella Herbert H. Seltzman P. Anantha Reddy
- Synthetic cannabinoids in Europe
- Pharmacological Effects of MDMA in Man. By Enno Freye
- Drug Use in Relation to Outcome of Mammography Screening. von Euler-Chelpin M, Wu W, Vejborg and Lynge E
- DEA Drug Scheduling
- Electrophysiological Effects of Trace Amines on Mesencephalic Dopaminergic Neurons.Ada Ledonne, Nicola Berretta, Alessandro Davoli, Giada Ricciardo Rizzo, Giorgio Bernardi and Nicola Biagio Mercuri
- Electrophysiological evidence for a reciprocal interaction between amphetamine and cocaine-related drugs on rat midbrain dopaminergic neurons.Scarponi M, Bernardi G, Mercuri NB.
- Overdose of Drugs for Attention-Deficit Hyperactivity Disorder: Clinical Presentation, Mechanisms of Toxicity, and Management. Henry A. Spiller, author Hannah L. Hays Alfred Aleguas.
- Dose-dependent effectiveness of wheel running to attenuate cocaine-seeking: impact of sex and estrous cycle in rats. Peterson AB, Hivick DP, Lynch WJ.r.
- FDA Drug Safety Communication: Safety Review Update of Medications used to treat Attention-Deficit/Hyperactivity Disorder (ADHD) in children and young adults
- ADHD Medications and Risk of Serious Cardiovascular Events in Young and Middle-aged Adults
- Controlled Substances Act
- The Art of Drug Synthesis (Wiley Series on Drug Synthesis)
- Cannabis: domestic cultivation widespread
- A review of the influence of functional group modifications to the core scaffold of synthetic cathinones on drug pharmacokinetics